Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) plus atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 29 May - 02 June 2026, vol.44, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 44
- Doi Number: 10.1200/jco.2026.44.16_suppl.8014
- City: Illinois
- Country: United States Of America
- Bursa Uludag University Affiliated: Yes